Yamo Pharmaceuticals Announces Positive Topline Results from Phase 2 Study of L1-79 for the Treatment of the Core Symptoms of Autism
30. Juli 2024 08:05 ET
|
Yamo Pharmaceuticals
Yamo Pharmaceuticals announces positive topline results from Phase 2 study evaluating L1-79 in adolescents and young adults with autism spectrum disorder
Yamo Pharmaceuticals Enrolls Final Patient in Phase 2 Study Evaluating L1-79 to Treat the Core Symptoms of Autism Spectrum Disorder
20. November 2023 08:05 ET
|
Yamo Pharmaceuticals
Yamo Pharmaceuticals LLC has completed enrollment in its Phase 2 study evaluating L1-79 in adolescents with autism spectrum disorder (ASD).
Yamo Pharmaceuticals Announces Enrollment of First Patient in Phase 2 Study of L1-79 in Autism Spectrum Disorder
27. Januar 2022 08:00 ET
|
Yamo Pharmaceuticals
New York, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Yamo Pharmaceuticals, a clinical stage pharmaceutical company developing a novel therapy for the core symptoms of autism spectrum disorder (ASD), today...
Yamo Pharmaceuticals Receives Investment from Autism Impact Fund to Support Phase 2 Study of L1-79 in Autism Spectrum Disorder
10. November 2021 14:00 ET
|
Yamo Pharmaceuticals
New York, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Yamo Pharmaceuticals, LLC, a clinical stage pharmaceutical company developing a novel therapy for the core symptoms of the autism spectrum disorder (ASD),...
Yamo Pharmaceuticals Presents Results from Phase 2 Study of L1-79 in Adolescents and Young Adult Males with Autism Spectrum Disorder at INSAR 2019
14. Mai 2019 08:01 ET
|
Yamo Pharmaceuticals
New York , May 14, 2019 (GLOBE NEWSWIRE) -- Yamo Pharmaceuticals, LLC, a clinical stage pharmaceutical company developing a novel therapy for autism spectrum disorder (ASD), announced the...
FDA Grants Fast Track Designation for Yamo Pharmaceutical’s L1-79 in Autism Spectrum Disorder
14. Mai 2018 08:00 ET
|
Yamo Pharmaceuticals
New York, May 14, 2018 (GLOBE NEWSWIRE) -- Yamo Pharmaceuticals, LLC, a clinical stage pharmaceutical company developing a novel therapy for autism spectrum disorder (ASD), announced today that the...